Quest Minerals & Mining to Start Full Coal Production at Pond Creek Mine at Slater's Branch
Friday , July 27, 2007 16:47ET
PATERSON, N.J., Jul 27, 2007 (BUSINESS WIRE) -- Quest Minerals & Mining Corp. (OTCBB: QMMG; Frankfurt: QMN.F), a Kentucky based operator of energy and mineral related properties, announced today that it is ready to start mining the new mine face at its Pond Creek Mine at Slater's Branch on Monday, July 30, 2007. Quest has completed its equipment installation at the new mine face and has completed its surveys on the new mine face location. It has also completed a sufficient enough portion of the rehabilitation to commence higher productivity operations.
Eugene Chiaramonte, Jr., President of Quest, stated, "We are very pleased to report that we are now at the new face at the Pond Creek Mine and are ready to start mining significant amounts of coal. During the ongoing rehabilitation, we have been producing 150 to 300 tons per day, as we needed to spend a substantial portion of our resources for rehabilitation and compliance with federal and state inspection agencies. We have substantially completed the rehabilitation, and we have completed our equipment installation and necessary surveys to mine the new mine face. We can now shift our primary focus from rehabilitation to coal production. The residual rehabilitation required should not interfere with production and should be complete by the end of next week.
"With this achievement, we anticipate that we will start producing between 500 to 700 tons of coal per day, starting Monday. This equates to 10,000 to 14,000 tons per month.
"As a result of this accomplishment, we now seek to establish a second shift at the mine to allow us to reach our goal of 20,000 tons per month. We are currently targeting Labor Day to reach this goal, and we believe that, with the progress we have made, we will reach that goal. In addition, this breakthrough will allow us to move forward with our plans to reopen the Lower Cedar Grove seam, located in Slater's Branch, and the Taylor seam, located in Hurricane Branch."
About Quest Minerals & Mining
Quest Minerals & Mining Corp., or Quest, acquires and operates energy and mineral related properties in the southeastern part of the United States. Quest focuses its efforts on properties that produce quality compliance blend coal. For more information on Quest Minerals & Mining Corp., please visit our website at www.questmining.net.
Forward-Looking Statements
This document contains discussion of items that may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Although Quest believes the expectations reflected in such forward-looking statements are based on reasonable assumptions, it can give no assurances that its expectations will be achieved. Factors that could cause actual results to differ from expectations include, but are not limited to, lack of revenue producing operations, lack of working capital, debt obligations, judgments and lien claims against Quest and certain of its assets, difficulties in refinancing short term debt, difficulties identifying and acquiring complementary businesses, fluctuations in coal, oil & gas, and other energy prices, general economic conditions in markets in which Quest does business, extensive environmental and workplace regulation by federal and state agencies, other general risks related to its common stock, and other uncertainties and business issues that are detailed in its filings with the Securities and Exchange Commission.
posted
DOR BioPharma Announces $940,000 FDA Orphan Products Grant for Clinical Development of RiVax(TM)
Monday , July 30, 2007 07:00ET
MIAMI, FL -- (MARKET WIRE) -- 07/30/07 -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company") announced today that the Office of Orphan Products Development (OOPD) of the Food and Drug Administration (FDA) has awarded a development grant for the further clinical evaluation of its vaccine for ricin toxin, RiVax(TM). The grant has been awarded to UT Southwestern Medical Center, one of the Company's academic partners in the development of RiVax(TM). The Principal Investigator for the project is Ellen S. Vitetta, PhD, Director of the Cancer Immunobiology Center at UT Southwestern. The award totals approximately $940,000 for three years and is to be used for the evaluation of an adjuvant for use with the vaccine. Typically, awards made by the OOPD are to support clinical trials for development of products that address rare diseases or medicines that would be used in numerically small populations.
RiVax(TM) was evaluated in a small dose escalating Phase 1 clinical trial in human volunteers conducted at UT Southwestern. It was shown to be well tolerated and immunogenic especially at the highest dose levels of the vaccine given three times at monthly intervals. The vaccine induced antibodies that were correlated to protection from toxin exposure, including the capacity to neutralize the toxin. Further, the functional activity of the antibodies was established by demonstrating that transfer of serum globulins from the vaccinated individuals to mice resulted in their survival subsequent to ricin toxin exposure. The results of that confirmatory trial underpin the current effort to develop an adjuvant form of the vaccine, which is intended to enhance human antibodies' responses to the vaccine and increase their durability and rapidity of onset.
RiVax(TM) is a recombinant subunit of one of the components of ricin toxin and has been genetically detoxified. The subunit is produced in recombinant bacterial hosts, purified, and formulated with an adjuvant.
"The Phase 1 clinical trial was done to establish that we had inactivated the toxin sufficiently to remove any possible local toxicity that could be associated with intramuscular injection," said Dr. Vitetta. "Having confirmed the fundamental immunogenicity in humans, we are ready to test the immunogenicity and safety of the vaccine with an adjuvant that we expect to induce long-lasting antibodies with lower doses of the vaccine."
"The award to UT Southwestern is one part of the overall development program, which includes large scale process development, stability testing, and development of animal models that demonstrate efficacy as correlates of the human immune response," said Christopher J. Schaber, PhD, President and Chief Executive Officer of DOR. "We are continuing to transition the early development of this vaccine from UT Southwestern to commercial production, and are relying on these results as the basis for broader Phase 2 studies of the vaccine in humans."
The Company has been developing RiVax(TM) in a consortium effort between academic and industrial partners under several separate NIAID grants totaling approximately $14 Million. In addition to UT Southwestern, development partners include, Stanford Research Institute (SRI International), the University of Kansas, Lonza Baltimore, and the Wadsworth Center of the New York State Department of Health in Albany. Complementing the current OOPD grant, Dr. Ellen Vitetta has also separately been awarded a grant for $2.2 million over 5 years to conduct research in fundamental areas to develop novel vaccine formulations and characterize immune responses in small animals. The outcome of that novel research will help support ongoing development of RiVax(TM).
About ricin toxin
Ricin toxin is a potent plant toxin easily produced from abundantly available castor beans. There is no vaccine to protect against exposure and no post-exposure therapeutic other than supportive care. Ricin is highly toxic to humans and other mammals and is thought to be a bioterror threat because of its environmental stability and high potency, second only to botulinum toxin as a natural toxin. Exposure to small amounts can lead to lung damage if inhaled, rapid onset of nausea, fever, and abdominal pain if ingested. General organ failure leading to death can occur within several days. The need for protective countermeasures against ricin has been emphasized by its recent and continued use as a biological weapon. The successful development of an effective vaccine against ricin toxin may act as a deterrent in the actual use of ricin as a biological weapon and can be used in rapid deployment scenarios in the event of a biological attack.
About the Office of Orphan Products Development.
The Office of Orphan Products Development (OOPD) is dedicated to promoting the development of products that demonstrate promise for the diagnosis and/or treatment of rare diseases or conditions since 1982. OOPD interacts with the medical and research communities, professional organizations, academia, and the pharmaceutical industry, as well as rare disease groups. The OOPD administers the major provisions of the Orphan Drug Act (ODA) which provide incentives for sponsors to develop products for rare diseases. The OOPD administers the Orphan Products Grants Program which provides funding for clinical research in rare diseases.
About DOR BioPharma, Inc.
DOR BioPharma, Inc. (DOR) is a biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec® (oral beclomethasone dipropionate), is a potent, locally acting corticosteroid being developed for the treatment of GI GVHD, a common and potentially life-threatening complication of bone marrow transplantation. DOR has filed an NDA for orBec® with the FDA for the treatment of GI GVHD, and subsequent to supplemental information recently submitted, the FDA has extended the PDUFA (Prescription Drug User Fee Act) date to October 21, 2007. An MAA (Marketing Authorization Application) with the EMEA (European Medicines Evaluation Agency) has also been filed and validated. orBec® may also have application in treating other gastrointestinal disorders characterized by severe inflammation. DOR has also recently initiated a development program with its Lipid Polymer Micelle (LPM(TM)) oral drug delivery technology for the oral delivery of leuprolide for the treatment of prostate cancer and endometriosis.
Through its Biodefense Division, DOR is developing biomedical countermeasures pursuant to the recently enacted Project BioShield Act of 2004. DOR's biodefense products in development are recombinant subunit vaccines designed to protect against the lethal effects of exposure to ricin toxin and botulinum toxin. DOR's ricin toxin vaccine, RiVax™, has been shown to be well tolerated and immunogenic in a Phase 1 clinical trial in normal volunteers.
For further information regarding DOR BioPharma, please visit the Company's website located at www.dorbiopharma.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, that reflect DOR BioPharma, Inc.'s current expectations about its future results, performance, prospects and opportunities, including statements regarding the potential use of orBec® for the treatment of gastrointestinal GVHD and the prospects for regulatory filings for orBec®. Where possible, DOR has tried to identify these forward-looking statements by using words such as "anticipates," "believes," "intends," or similar expressions. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec®, particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its technologies will prove to be safe and effective, that its cash expenditures will not exceed projected levels, that it will be able to obtain future financing or funds when needed, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the U.S. Government or other countries, that the U.S. Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: because orBec® did not achieve statistical significance in its primary endpoint in the pivotal Phase 3 clinical study (i.e. a p-value of less than or equal to 0.05), the Oncologic Drug Advisory Committee ("ODAC") appointed by the FDA voted that the data supporting orBec® did not show substantial evidence of efficacy by a margin of 7 to 2 for the treatment of GI GVHD, although the FDA is not bound by ODAC's decision, the FDA may not consider orBec® approvable based upon existing studies, orBec® may not show therapeutic effect or an acceptable safety profile in future clinical trials, if required, or could take a significantly longer time to gain regulatory approval than DOR expects or may never gain approval; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; or orBec® may not gain market acceptance; and others may develop technologies or products superior to orBec®. These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Form 10-QSB and Form 10-KSB. DOR assumes no obligation to update or revise any forward-looking statements as a result of new information, future events, and changes in circumstances or for any other reason.
-------------------------------------------------------------------------------- Company Contact: Evan Myrianthopoulos Chief Financial Officer (786) 425-3848 www.dorbiopharma.comSource: DOR BioPharma, Inc.
-------------------- " Cash is King "
IP: Logged |
posted
MortgageBrokers.com announces the expansion of its brand presence through opening new retail locations across Canada
Monday , July 30, 2007 08:18ET
TORONTO, Jul 30, 2007 (Canada NewsWire via COMTEX) -- MortgageBrokers.com Financial group of Companies Inc., a subsidiary of MortgageBrokers.com Holdings Inc. (OTC BB: MBKR - News) announced that the company through it's Managing Partner, opening of 2 new retail locations under the MortgageBrokers.com flag in Toronto, Ontario. These latest retail store front opening continues the company's expanding brand presence through store front retail locations across Canada.
"These 2 new locations are part of our continued commitment toward building our presence and brand awareness in the attractive mortgage markets. While our intention is to build an international footprint over time, we believe we can support our Managing Partners open many new, robust locations across North America. With our unique business model, we are able to open locations without significant capital outlays, and we intend to do so in a rationale and methodical manner for the foreseeable future," said Alex Haditaghi, CEO and Founder of MortgageBrokers.com. "Because all of our mortgage sales team are owners and shareholders of the company we tend to attract those that are looking towards building long careers in this industry and a strong presence in their communities by sharing our belief that retail locations strengthens our brand and our relationship with our customers," concluded Mr. Haditaghi.
These two (2) retail locations are owned and operated by company's Managing partner, David Ross, who has had a long tenure in this industry. Mr. Ross commented that, "both my team and I strongly believe in the business model of MortgageBrokers.com and recognized that opening up new retail locations under the MortgageBrokers.com brand was the natural next step towards leveraging the brand recognition."
The company continues to open new retail locations organically but also through the company's exclusive revenue licensing agreements with Mortgage Brokerages and brokers who through these agreements are converting their retail locations to MortgageBrokers.com.
About MortgageBrokers.com
-------------------------
MortgageBrokers.com is dedicated to re-branding of over 40,000 small and medium mortgage broker (SME) firms in North America while providing these entities scalability through a centralized shared services platform. MortgageBrokers.com consolidation strategy is based on vision of combining small and medium sized mortgage brokerage enterprises (SME) into one stronger, leaner, and highly efficient operating entity that can better compete in the industry under one recognizable brand. The prime objective is to improve the economic performance of the combined companies though the reduction of operating costs, expansion of a national brand and improved market share. The Company also expects growth to be catalyzed by a rising interest rate environment. The main reasons for this are as follows:
* MortgageBrokers.com shared services model will allow SME brokerages
to reduce their overheads on the centralization of back office tasks that
include accounting, compliance, human resources, technology, marketing,
payroll and loan processing.
* MortgageBrokers.com lead generation system, national brand and
technology platform will allow SME brokers to acquire new customers,
better serve their current customers by focusing on sales, get more
repeat business through our CRM solution and scalability through the
reduction of back office responsibilities.
* In high interest rate market conditions, consumers will demand bigger
interest rate discounts. MortgageBrokers.com business strategy of
amalgamating SME brokerages will lead to better leverage with lenders for
revenue generation and rate discretion, through the pooling of
origination volumes and control over channeling of mortgage volume.
* MortgageBrokers.com will work towards the diversification of income
and revenue sources. Our partnerships with credit card, title insurance,
home and auto insurance, cable, long distance, internet and eventually
in-house lending will enable us to expand and diversify our revenue
Statements included in this press release, which are not historical in nature, are intended to be, and are hereby identified as 'Forward-Looking Statements' for purposes of safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended. Forward-Looking Statements may be identified by words including 'anticipate,' 'await,' 'envision,' 'foresee,' 'aim at,' 'plans,' 'believe,' 'intends,' 'estimates,' 'expects' and 'projects' including without limitation, those relating to the company's future business prospects, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the Forward-Looking Statements. Readers are directed to the company's filings with the U.S. Securities and Exchange Commission for additional information and a presentation of the risks and uncertainties that may affect the company's business and results of operations. www.sec.gov
For further information please contact Mr. Jody Janson,
Ph: (585) 232-5440.
SOURCE: MortgageBrokers.com Inc.
SOURCE: MortgageBrokers.com Holdings, Inc.
Mr. Jody Janson, Ph: (585) 232-5440
Copyright (C) 2007 CNW Group. All rights reserved.
-------------------- " Cash is King "
IP: Logged |
BOCA RATON, Fla., Jul 30, 2007 (BUSINESS WIRE) -- Med Gen Inc. (OTCBB:MGEN) ("MGEN"), manufacturers of nationally branded OTC healthier life products and financial services business, reports increasing demand and sales for ARO-SNORING RELIEF, Med Gen's Australian branded snoring relief formula. "In the past 9 months, Australian sales have exceeded 69,000 bottles, with new orders in July reaching 15,000 bottles," reported Paul S. Mitchell, President/C00.
"We have invested heavily in time and capital resources to pave the way for distribution of our patented snoring formula in countries outside of the United States," said Paul Kravitz, Chairman/CEO. "The approval and distribution process in many cases has taken 2-3 years before shipping can start. Yet, rewards can be significant when they are measured against all the costs. This is proving to be the case in Australia where sales have already exceeded $157,000 and growing. New packaging is being readied to penetrate the markets of Singapore, Vietnam and Hong Kong. Snoring is a universal problem," said Kravitz.
Much of Med Gen's success in Australia is owed to Aurios, PTY LTD., its overseas distributor, who has also invested heavily alongside Med Gen believing in the long-term success of Med Gen's proven patented formula.
About Med Gen Inc.
Med Gen Inc., in business since 1996, manufactures and markets specialty products using its proprietary delivery system Spray's the Way ("STW"). It is best known for producing the world's first patented liquid spray snoring relief formula, Snorenz(R). Since its existence, Med Gen has continued to develop its STW technology, introducing Good Nights Sleep(R) and the UnDiet(R) system into its family of brands. While STW technology is mainly used, the company also produces other products that deal with common health issues using other delivery systems. Recently, the company formed a joint venture to market FootFridge(R) an innovative and patented innersole, that amongst other attributes, cools and comforts the feet. The company markets its products to distributors, major chain and drug stores, direct sales via the company web site and direct to consumer television, radio and print advertising. The company also distributes its brands internationally under various private labels or existing names. The Company also offers specialty services to small emerging public companies in similar fields as a way of adding assets to its base business.
Med Gen Inc. is a fully reporting company whose stock trades on the OTCBB under the symbol "MGEN". For information contact Investor Relations 561-750-1100 or www.medgen.com.
This Press Release contains or incorporates by reference "forward looking statements" including certain information with respect to plans and strategies of Med Gen Inc. For this purpose, any statements contained herein or incorporated herein by references that are not statements of historical fact may be deemed forward looking statements. Without limiting the foregoing, the words "believes", "suggests", "anticipates", "plans", "expects", and similar expressions are intended to identify forward looking statements. There are a number of events or actual results of Med Gen operations that could differ materially from those indicated by such forward looking statements.
SOURCE: Med Gen Inc.
Med Gen Inc., Boca Raton Paul Kravitz, 561-750-1100 www.medgen.com
Copyright Business Wire 2007
-------------------- " Cash is King "
IP: Logged |
Rail Spur Installation at Continental Fuels' Brownsville Facility - Cost to be Borne by New Customer - Additional Storage and Delivery Methods to Result
Monday , July 30, 2007 06:29ET
PORT OF BROWNSVILLE, Texas, Jul 30, 2007 (BUSINESS WIRE) -- Continental Fuels, Inc. (OTCBB:CFUL) (FWB:CNDI) (GER:CNDI) (BCN:CNDI) has entered a new agreement for the sale of 40,000 - 60,000 barrels per month of light crude condensate to be delivered via rail. As part of this agreement, this new customer has agreed to bear the cost of construction of a railroad spur and loading station at the Port of Brownsville.
The customer has also purchased 54 rail cars with a capacity of 675 barrels each. These rail cars will be stored at Continental's facility at the Port of Brownsville, effectively increasing the storage capacity at the facility by another 36,000 barrels. Together with the storage tanks being relocated to Brownsville, Continental will have increased its capacity by over 100% upon completion of these projects within the next 3 weeks.
Work on the rail spur will be immediately commenced. It will service sixteen 60 foot rail cars and the loading station will simultaneously fill 3 at a time. Deliveries to the new customer are scheduled to begin during the month of August.
Continental Fuels, Inc. is a subsidiary of Universal Property Development and Acquisition Corporation (OTCBB:UPDA) (FWB:UP1) (BCN:UP1) (GER:UP1) (MUN:UP1) (STU:UP1).
Statements contained in this press release that are not based upon current or historical fact are forward-looking in nature. Such forward-looking statements reflect the current views of management with respect to future events and are subject to certain risks, uncertainties, and assumptions. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated, expected, or described pursuant to similar expressions.
SOURCE: Continental Fuels, Inc.
Continental Fuels Jack Baker, 561-630-2977 Corporate Communications info*continentalfuels.com
Copyright Business Wire 2007
-------------------- " Cash is King "
IP: Logged |
posted
DC Brands Vegas Shareholder Meeting a Success
Monday , July 30, 2007 06:00ET
DENVER, CO -- (MARKET WIRE) -- 07/30/07 -- DC Brands International (PINKSHEETS: DCBI) completed its Las Vegas shareholder meeting over the weekend and is thrilled with the turnout. The company held its meeting at The Palms Casino Resort in the largest movie theater on property with a reception at the ultra-swank Moon nightclub following. A DVD of the event will be available to all shareholders in the next few weeks.
"The meeting and reception were an overwhelming success, and we can't thank enough all the dedicated shareholders from around the country who traveled to Las Vegas for our event," said President and CEO Richard Pearce. "The face time we get with shareholders is invaluable for our company's progress, and while we enjoy opportunities to announce the news that we did, we also appreciate the candid feedback given to us. There was so much information presented during the meeting that we will be announcing it in more detailed releases throughout the next few weeks."
The meeting was kicked off by a live performance from the Purrfect Angelz, also known as the Turn Left calendar girls, and followed by a video montage of the company's product and promotions. Nearly ten different DC Brands champions provided brief updates interspersed with those provided by Pearce.
After the meeting, all attendees headed to Moon, the premier nightclub in The Palms, where guests enjoyed food and drinks and helped to raise money for DC Brands' newest endorsed charity -- Turn Left for the Cure. DC Brands raffled off several items, including autographed jackets and tickets to the Daytona 500, and matched the proceeds to donate to Turn Left for the Cure.
For more information on DC Brands International, visit their website at www.TurnLeftEnergy.com and DickensEnergyCider.com.
Note: Except for the historical information contained herein, this news release contains forward-looking statements that involve substantial risks and uncertainties. Among the factors that could cause actual results or timelines to differ materially are risks associated with research and clinical development, regulatory approvals, supply capabilities and reliance on third-party manufacturers, product commercialization, competition, litigation, and the other risk factors listed from time to time in reports filed by DC Brands International with the Securities and Exchange Commission, including but not limited to risks described under the caption "Important Factors That May Affect Our Business, Our Results of Operation and Our Stock Price." The forward-looking statements contained in this news release represent judgments of the management of DC Brands International as of the date of this release. DC Brands International and its managers and agents undertake no obligation to publicly update any forward-looking statements.
-------------------------------------------------------------------------------- CONTACT: Aubrey Cornelius acornelius*dc-brands.com
Source: DC Brands International, Inc.
-------------------- " Cash is King "
IP: Logged |
Diamant Art Corporation Receives a Further Order for More Than 8 MILLION Feet of Its Bio-Degradable Cling Film
Monday , July 30, 2007 09:00ET
TORONTO -- (MARKET WIRE) -- 07/30/07 -- Diamant Art Corporation (OTCBB: DIAAF) is pleased to announce that through its wholly owned subsidiary, Bio-Plastics Film Inc., that it has received an order for immediate shipping of more than 8 MILLION feet of its biodegradable cling film and will be shipped directly by Diamant to NNZ's customer Produce Packaging, Inc. of Cleveland, Ohio. The order is from one of Diamant's distributors NNZ Inc. www.NNZUSA.com a company with offices both in the United States and Europe and whose focus is in the introduction of biodegradable cling film to the produce industry in the United States.
This order further demonstrates the growing interest by companies/buyers in the United States to seek out and buy sustainable environmentally friendly packaging products. With the increase awareness being generated in the United States to deal with environmental issues, it is expected that this interest for biodegradable products will continue to grow in the coming months.
Mr. Stefan Gudmundsson, CEO of Diamant, stated, "We are continuing to make great strides in developing our distributor network through our reputation for manufacturing great products in the most environmentally friendly way possible."
About Diamant Art Corporation
Diamant Art Corporation, through its wholly owned subsidiary Diamant Film Inc., distributes Diamant(TM) film, the world's first plasticizer-free stretch film based on polystyrene and the first food wrap film that is environmentally friendly and recyclable. Diamant(TM) film has recently received the ECO logo certified by the Environmental Choice(M) Program. The Environmental Choice(M) Program is North America's leading benchmark of environmentally responsible products and services. Diamant(TM) film has successfully met the criteria for both the environmental and performance standards and through its wholly owned subsidiary Bio-Plastics Film Inc. it supplies bio-degradable food cling, bags, stretch and pallet wrap films. All of Diamant's bio-film products are ideal product in the most environmentally friendly way possible.
Safe Harbor
This release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 6-K or 20F and other filings made by such company with the SEC. Further Diamant Art Corporation and its wholly owned subsidiaries, Diamant Film Inc and Bio-Plastics Film Inc. do not condone or participate in spam activities, e-mail and fax programs of any manner.
-------------------------------------------------------------------------------- Contact: Stefan Gudmundsson CEO and President Diamant 905-752-0220
Source: Diamant Art Corporation
-------------------- " Cash is King "
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
